Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from Merck & Co., Inc.

Oncology Consultations®: The Evolving Treatment Landscape for Triple-Negative Breast Cancer: What Clinicians Need to Know

Release Date: September 14, 2021
Expiration Date: September 14, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in the treatment of triple-negative breast cancer (TNBC). In this educational program, these experts use a case-based format to discuss current and emerging therapeutic strategies for treating patients with TNBC, including PARP inhibitors, immune checkpoint inhibitors, and an anti-Trop-2 antibody-drug conjugate.

This educational activity is an archive of the live virtual symposium held on August 19, 2021.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This activity is intended for medical oncologists and other healthcare professionals who manage patients with breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe the distinct pathophysiologic characteristics of triple-negative breast cancer (TNBC) and explain the rationales for different targeted therapeutic approaches
  • Discuss the efficacy and safety of current treatment options for patients with TNBC as well as patient selection criteria for specific agents and adverse event management strategies
  • Utilize appropriate biomarkers and patient characteristics to develop individualized treatment plans for patients with TNBC
  • Review recent results from clinical trials evaluating novel agents for TNBC, including PARP inhibitors, immune checkpoint inhibitors, antibody-drug conjugates, PI3K inhibitors, and other molecularly targeted approaches, alone and in combination with conventional cytotoxic regimens, to address unmet clinical needs

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.


Hope S. Rugo, MD, FASCO
Hope S. Rugo, MD, FASCO
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Disclosures: Grant/Research Support: AstraZeneca; Ayala Pharmaceuticals; Boehringer Ingelheim; Daiichi-Sankyo, Inc.; Eli Lilly & Co.; Gilead Sciences, Inc.; MacroGenics; Merck & Co., Inc.; Novartis; Pfizer Inc.; Polyphor; Roche; Seagen Inc.; Sermonix Pharmaceuticals.

Sara M. Tolaney, MD, MPH
Sara M. Tolaney, MD, MPH
Associate Director
Susan F. Smith Center for Women’s Cancer
Director of Clinical Trials, Breast Oncology
Director of Breast Immunotherapy Clinical Research
Senior Physician
Breast Oncology Program
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Consultant: AstraZeneca; Athenex; Bristol Myers Squibb; Chugai Pharmaceutical; CytomX; Daiichi-Sankyo, Inc.; Eisai; Eli Lilly & Co.; Merck & Co, Inc.; NanoString; Nektar; Novartis; OncoPep; Pfizer Inc.; Seagen Inc.; Other Support: Advisory Board: 4D pharma; AstraZeneca; BeyondSpring Inc.; Bristol Myers Squibb; Celldex Therapeutics; Certara; Eisai; Eli Lilly & Co.; Ellipses Pharma; G1 Therapeutics; Genentech/Roche; Immunomedics/Gilead; Kyowa Kirin Pharmaceuticals; Mersana Therapeutics; Merck & Co, Inc.; NanoString; Nektar; Novartis; OncoSec Medical Incorporated; Pfizer Inc.; Puma Biotechnology; Samsung Bioepis Inc.; Sanofi; Silverback Therapeutics; Steering Committee: CytomX; Eli Lilly & Co.; Odonate; OncXerna Therapeutics; PI of Studies: AstraZeneca; Bristol Myers Squibb; Cyclacel Pharmaceuticals; Eisai; Eli Lilly & Co.; Exelixis; Genentech/Roche; Immunomedics/Gilead; Merck; NanoString; Nektar; Novartis; Odonate Therapeutics; Pfizer Inc.; Sanofi; Seagen Inc.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By